Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2011-04-05
2011-04-05
Blanchard, David J. (Department: 1643)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C424S133100, C424S141100, C424S143100, C424S155100, C435S070210, C530S387300, C530S388100, C530S388220, C530S388800
Reexamination Certificate
active
07919273
ABSTRACT:
The present invention provides substituted humanized, chimeric or human anti-CD20 antibodies or antigen binding fragments thereof and bispecific antibodies or fusion proteins comprising the substituted antibodies or antigen binding fragments thereof. The antibodies, fusion proteins or fragments are useful for treatment of B-cell disorders, such as B-cell malignancies and autoimmune diseases, as well as GVHD, organ transplant rejection, and hemolytic anemia and cryoglobulinemia. Amino acid substitutions, particularly substitution of an aspartate residue at Kabat position 101 of CDR3 VH(CDRH3), result in improved therapeutic properties, such as decreased dissociation rates, improved CDC activity, improved apoptosis, improved B-cell depletion and improved therapeutic efficacy at very low dosages. Veltuzumab, a humanized anti-CD20 antibody that incorporates such sequence variations, exhibits improved therapeutic efficacy compared to similar antibodies of different CDRH3 sequence, allowing therapeutic effect at dosages as low as 200 mg or less, more preferably 100 mg or less, more preferably 80 mg or less, more preferably 50 mg or less, most preferably 30 mg or less of naked antibody when administered i.v. or s.c.
REFERENCES:
patent: 4036945 (1977-07-01), Haber
patent: 4046722 (1977-09-01), Rowland
patent: 4331647 (1982-05-01), Goldenberg
patent: 4699784 (1987-10-01), Shih
patent: 4704692 (1987-11-01), Ladner
patent: 4824659 (1989-04-01), Hawthorne
patent: 4946778 (1990-08-01), Ladner
patent: 5057313 (1991-10-01), Shih
patent: 5229275 (1993-07-01), Goroff
patent: 5443953 (1995-08-01), Hansen
patent: 5530101 (1996-06-01), Queen et al.
patent: 5567610 (1996-10-01), Borrebaeck
patent: 5633425 (1997-05-01), Lonberg
patent: 5734033 (1998-03-01), Reed
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5776456 (1998-07-01), Anderson et al.
patent: 5798554 (1998-08-01), Grimaldi
patent: 5827690 (1998-10-01), Meade
patent: 6077499 (2000-06-01), Griffiths
patent: 6183744 (2001-02-01), Goldenberg
patent: 6187287 (2001-02-01), Leung
patent: 6254868 (2001-07-01), Leung
patent: 6331175 (2001-12-01), Goldenberg
patent: 6897044 (2005-05-01), Braslawsky et al.
patent: 7074403 (2006-07-01), Goldenberg et al.
patent: 7151164 (2006-12-01), Hansen
patent: 7321026 (2008-01-01), Leung
patent: 7338659 (2008-03-01), Leung
patent: 7435803 (2008-10-01), Hansen
patent: 2002/0004587 (2002-01-01), Miller et al.
patent: 2002/0009427 (2002-01-01), Wolin et al.
patent: 2002/0009444 (2002-01-01), Grillo
patent: 88/04936 (1988-07-01), None
patent: 92/07466 (1992-05-01), None
patent: 94/11026 (1994-05-01), None
patent: 00/29584 (2000-05-01), None
patent: 0044788 (2000-08-01), None
patent: 00/63403 (2000-10-01), None
patent: 02056910 (2002-07-01), None
patent: 03002607 (2003-01-01), None
Goldenberg D. M. et al. Blood, 113(5):1062-1070, Jan. 29, 2009.
“An Extended Primer Set for PCR Amplification of Murine Kappa Variable Regions,”BioTechniques, Aug. 1993, vol. 15, No. 2.
Ansel, et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, Fifth Edition, 1990.
Appelbaum, “Radiolabeled Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma,”Hematology/Oncology Clinics of North America, Oct. 1991, pp. 1013-1025, vol. 5, No. 5, W.B. Saunders Company, Harcourt Brace Jovanovich, Inc., Philadelphia London Toronto Montreal Sydney Tokyo.
Frederick M. Ausubel, et al. (Eds.), “Current Protocols in Molecular Biology,” 1994, vol. 1, John Wiley & Sons, Inc. & Current Protocols, Published simultaneously in Canada.
Baines, et al., “Purification of Immunoglobulin G (IgG),”Methods in Molecular Biology, 1992, pp. 79-105, vol. 10, chapter 8, Immunochemical Protocols, The Humana Press, Inc., Totowa, New Jersey.
Barnes, et al., “Advances in animal cell recombinant protein production: GS-NSO expression system,”Cytotechnology, 2000, 109-123, 32, 2000 Kluwer Academic Publishers, Netherlands.
Bird, et al., “Single chain antibody variable regions,”Tibtech, Apr. 1991, pp. 132-137, vol. 9, Elsevier Science Publishers Ltd., United Kingdom.
Caron, et al., “Brief Definitive ReportEngineered Humanized Dimeric Forms of IgG Are More Effective Antibodies,”J. Exp. Med., Oct. 1992, pp. 1191-1195, vol. 176, The Rockefeller University Press.
Carter, et al., “Humanization of an anti-p185HER2antibody for human cancer therapy,”Proc. Natl. Acad. Sci. USA, Immunology, May 1992, pp. 4285-4289, vol. 89.
Cochlovius, et al., “Advances in BriefCure of Burkitt's Lymphoma in Severe Combined Immunodeficiency Mice by T Cells, Tetravalent CD3 ×CD19 Tandem Diabody, and CD28 Costimulation1,”Cancer Research, Aug. 15, 2000, pp. 4336-4341, vol. 60, Germany.
Colman, “Production of therapeutic proteins in the milk of transgenic livestock,”Biochem. Soc. Symp., pp. 141-147, 63, Portland Press, United Kingdom, 1996.
Coloma, et al., “Design and production of novel tetravalent bispecific antibodies,”Nature Biotechnology, Feb. 1997, pp. 159-163, vol. 15.
Courtenay-Luck, “Genetic manipulation of monoclonal antibodies”Genetic manipulation of monoclonal antibodies, 1995, pp. 166-179, First published University Press, Cambridge, United Kingdom, Press Syndicate of the University of Cambridge, New York.
Devesa, et al., “Cancer Incidence and Mortality Trends Among Whites in the United States, 1947-48,”JNCi, Oct. 1987, pp. 701-770, vol. 79, No. 4, National Cancer Institute, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health.
Eary, et al., “Imaging and Treatment of B-Cell Lymphoma,”The Journal of Nuclear Medicine, Aug. 1990, pp. 1257-1268, vol. 31, No. 8, The Official Publication of The Society of Nuclear Medicine, Inc.
Fitzgerald, et al., “Improved tumour targeting by disulphide stabilized diabodies expressed inPichia pastoris,” Protein Engineering, 1997, pp. 1221-1225, vol. 10, No. 10, Oxford University Press, United Kingdom.
Foon, et al., “Chronic Lymphocytic Leukemia: New Insights into Biology and Therapy,”Annals of Internal Medicine, Oct. 1, 1990, pp. 525-539, vol. 113, No. 7, Published twice monthly by the American College of Physicians.
Freedman, “Immunobiology of Chronic Lymphocytic Leukemia,”Hematology/Oncology Clinics of North America, Apr. 1990, vol. 4, No. 2, W.B. Saunders Company, Harcourt Brace Jovanovich, Inc., Philadelphia London Toronto Montreal Sydney Tokyo.
Freedman, et al., “XXXVI-10 Non-Hodgkin's Lymphomas,”CancerMedicine—Third Edition, 1993, pp. 2028-2068, vol. 2, Lea & Febiger, Philadelphia, London.
Gennaro, “Remington: Practice of,” 19thEdition,The Science and Pharmacy, 1995, Mack Publishing Company, United States.
Ghetie, et al., “Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells,” Immunology,Proc. Natl. Acad. Sci. USA, Jul. 1997, pp. 7509-7514, vol. 94, The National Academy of Sciences, USA.
Ghetie, et al., “Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin,”Blood, Mar. 1, 2001, pp. 1392-1396, vol. 97, No. 5, The American Society of Hematology, USA.
Ghetie, et al., “Evaluation of Ricin a Chain-containing Immunotoxins Directed against CD19 and CD22 Antigens on Normal and Malignant Human B-Cells as Potential Reagents for in Vivo Therapy1,”Cancer Research, 1988, pp. 2610-2617, vol. 48, No. 9.
Gillies, et al., “High-level expression of chimeric antibodies using adapted cDNA variable region cassettes,”Journal of Immunological Methods, 1989, pp. 191-202, vol. 125, Elsevier Science Publishers B.V. (Biomedical Division), USA.
Goldenberg, “New Developments in Monoclonal Antibodies for Cancer Detection and Therapy,”CA-A Cancer Journal for Clinicians, Jan./F
Chang Chien-Hsing
Goldenberg David M.
Hansen Hans J.
Blanchard David J.
Immunomedics Inc.
Rossi Kimms & McDowell LLP
LandOfFree
Structural variants of antibodies for improved therapeutic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Structural variants of antibodies for improved therapeutic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Structural variants of antibodies for improved therapeutic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2701073